Announcement on Voluntary Disclosure of the Approval for Market Launch of Siromivimab Injection for Passive Immunization Indication in Adults Exposed to Rabies Virus

About this update from Chongqing Genrix Biopharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of the Approval for Market Launch of Siromivimab Injection for Passive Immunization Indication in Adults Exposed to Rabies Virus The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Chongqing Genrix Biopharmaceutical Co., Ltd. Class A